

NovaSterilis Receives Patent for Vaccine Creation Using Supercritical Carbon Dioxide

ITHACA, NY, July 14, 2009 – NovaSterilis Inc., Lansing NY, a leader in the development and commercialization of supercritical carbon dioxide technology for biomedical applications, announces the issue of US Patent Serial #7,560,113 for creation and production of whole cell vaccines with supercritical carbon dioxide (SCCO₂).

Utilizing supercritical carbon dioxide technology the NovaSterilis research and development team performed a number of experiments investigating immune response to a SCCO₂ inactivated bacterial pathogen. Data accumulated from the research indicated that the technology was capable of producing a fast and effective vaccine in response to bacterial pathogens. The NovaSterilis technology completely inactivated the pathogen, caused no adverse reactive response, and the test subject demonstrated accumulated antibodies (immune recognition) upon a challenge. A key component of this process is the speed in which the technology inactivated the pathogen without destruction of the structures vital to immune response.

“We are excited that our technology may hold the key to developing an immediate therapeutic response to infectious agents, providing the scientific community another tool to respond to pandemics or biologic threats” stated David Burns, President and CEO.

About NovaSterilis

NovaSterilis currently markets terminal sterilization technology and equipment built on their supercritical carbon dioxide platform. The supercritical or the fluid phase of CO₂ occurs at low pressure (72.9 atm) and moderate temperatures (31.1° C). Supercritical CO₂ retains advantageous properties of the gas and liquid phases of carbon dioxide making it an ideal fluid for manufacturing processes. The company currently markets the Nova 2200, a 20 liter fully automated supercritical CO₂ terminal sterilization chamber and is in final development of an 80 liter unit. NovaSterilis is a privately held biotechnology company located in Lansing New York. NovaSterilis is the recipient of a 2007 Presidents Green Chemistry Award presented by the Environmental Protection Agency. For more information on NovaSterilis and supercritical carbon dioxide visit www.novasterilis.com

The foregoing release contains forward-looking statements that can be identified by language such as “produced” and “immediate”, for example, or by express or implied statements regarding the value of this technology. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause future results with supercritical carbon dioxide technologies to differ from any previous research. There can be no guarantee that SCCO₂ will produce marketed clinical vaccines for sale in any market. Nor can there be any guarantee that the use of SCCO₂ to produce therapeutic vaccines will achieve any particular levels of revenue in the future.